Mink Therapeutics Q2 2024 Earnings Report
Key Takeaways
MiNK Therapeutics reported its second quarter 2024 results, highlighting the advancement of its iNKT programs, particularly agenT-797 in a Phase 2 study for second-line gastric cancer, and the fast-tracking of IND-enabling activities for MiNK-215. The company's cash balance at the end of the quarter was $9.3 million, with a net loss of $2.7 million, or $0.07 per share.
AgenT-797 is progressing in a Phase 2 study for second-line gastric cancer.
IND-enabling activities for FAP-expressing CAR-iNKT therapy, MiNK-215, are being fast-tracked.
Expanded findings underscore agenT-797's potential in treating severe respiratory conditions in immune-compromised patients.
MiNK is committed to expanding the development of agenT-797 in areas of ARDS and GvHD.